Receiving any medications or substances that are strong or moderate inhibitors of CYPA; use of strong or moderate inhibitors are prohibited =<  days prior to randomization
Patients receiving treatment with medications that meet one of the following criteria and that cannot be discontinued at least  week prior to the start of treatment with INC and for the duration of the study:\r\n* Strong and moderate inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA)\r\n* Strong inducers of CYPA\r\n* Proton pump inhibitors (PPI)
Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA); use of the strong or moderate inhibitors are prohibited =<  days prior to registration
Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P family , subfamily A, polypeptide  (CPY A); use of the following strong or moderate inhibitors are prohibited =<  days prior to registration:\r\n* Strong inhibitors of cytochrome P family , subfamily A, polypeptide  (CYPA): indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, telithromycin\r\n* Moderate inhibitors of CYPA: aprepitant, erythromycin, fluconazole, grapefruit juice, verapamil, diltiazem
Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P, family , subfamily C, polypeptide  (CYP CYPC); use of the following strong or moderate inhibitors are prohibited =<  days prior to registration\r\n* Strong or moderate inhibitors of cytochrome P, family , subfamily C, polypeptide  (CYPC): gemfibrozil, trimethoprim
Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P, family , subfamily C, polypeptide  (CYP CYPC); use of the following strong or moderate inhibitors are prohibited =<  days prior to registration\r\n* Strong or moderate inhibitors of cytochrome P, family , subfamily C, polypeptide  (CYPC): fluconazole, amiodarone
Patients who are currently receiving treatment with drugs known to be moderate or strong inhibitors or inducers of isoenzymes cytochrome P, family , subfamily A, polypeptide  (CYPA) or cytochrome P, family , subfamily C, polypeptide  (CYPC); the patient must have discontinued moderate and strong inducers of both enzymes for at least one week and must have discontinued strong and moderate inhibitors before the start of treatment; switching to a different medication prior to start of treatment is allowed
Any medications which are strong or moderate cytochrome P, family , subfamily A (CYPA) inhibitors or strong CYPA inducers
Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA); use of strong or moderate inhibitors are prohibited =<  days to registration
Foods or medications that are strong or moderate inhibitors or inducers of cytochrome P, family , subfamily A (CYPA) taken within  week prior to study treatment and for the duration of the study
Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA)\r\n* Use of strong or moderate inhibitors is prohibited =<  days prior to registration
Concurrent use of moderate to strong cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors is not allowed
Currently taking strong or moderate inhibitors/inducers of cytochrome P, family , subfamily A, polypeptide  (CYPA); Note: dinaciclib is a CYPA substrate; patients should not take grapefruit/grapefruit juice or St. John's wort; use of strong or moderate CYPA inhibitors is prohibited from <  days prior to registration; use of CYPA inducers is prohibited from =<  days prior to registration
Receiving any medications or substances that are inducers or strong or moderate inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) =<  days prior to registration\r\n* Use of CYPA inducers are prohibited =<  days prior to registration\r\n* Use of CYPA strong or moderate inhibitors are prohibited =<  days prior to registration